Outcomes | Ventilator-Associated Pneumonia | Medtronic

Mortality Rates in Patients with VAP Versus Controls

Back

Mortality Rates in Patients with VAP Versus Controls

	VAP Mortality	Control Mortality	Difference
Bercault 2001([FOOTNOTE=Bercault N, Boulain T. Mortality rate attributable to ventilator-associated nosocomial pneumonia in an adult intensive care unit: a prospective case-control study. Crit Care Med. 2001;29(12):2303-2309. ],[ANCHOR=View Abstract],[LINK=/content/covidien/websites/medtronic/com/en/covidien/support/clinical-evidence.html?id=805224]) (p< 0.0001)	41.00%	14.00%	27.00%
Warren 2003([FOOTNOTE=Warren DK, Shukla SJ, Olsen MA, et al. Outcome and attributable cost of ventilator-associated pneumonia among intensive care unit patients in a suburban medical center. Crit Care Med. 2003;31(5):1312-1317.],[ANCHOR=View Abstract],[LINK=/content/covidien/websites/medtronic/com/en/covidien/support/clinical-evidence.html?id=277904]) (p< 0.001)	50.00%	34.00%	16.00%
Rello 2002([FOOTNOTE=Rello J, Ollendorf DA, Oster G, et al. Epidemiology and outcomes of ventilator-associated pneumonia in a large US database. Chest. 2002;122(6):2115-2121.],[ANCHOR=View Abstract],[LINK=/content/covidien/websites/medtronic/com/en/covidien/support/clinical-evidence.html?id=805225]) (p< 0.713)	30.50%	30.40%	0.10%
Ibrahim 2001([FOOTNOTE=Ibrahim EH, Tracy L, Hill C, Fraser VJ, Kollef MH. The occurrence of ventilator-associated pneumonia in a community hospital: risk factors and clinical outcomes. Chest. 2001;120(2):555-561. ],[ANCHOR=View Abstract],[LINK=/content/covidien/websites/medtronic/com/en/covidien/support/clinical-evidence.html?id=805222]) (p< 0.004)	45.50%	32.20%	13.30%
Kollef 2005([FOOTNOTE=Kollef MH, Shorr A, Tabak YP, Gupta V, Liu LZ, Johannes RS. Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia. Chest. 2005;128(6):3854-3862.],[ANCHOR=View Abstract],[LINK=/content/covidien/websites/medtronic/com/en/covidien/support/clinical-evidence.html?id=805226]) (p< 0.0001)	29.30%	10.00%	19.30%

VAP - Attributable Mortality at 30 and 60 Days

Back

VAP - Attributable Mortality at 30 and 60 Days

	Attributable Mortality
Bekaert 2011([FOOTNOTE=Bekaert M, Timsit JF, Vansteelandt S, et al. Attributable mortality of ventilator-associated pneumonia: a reappraisal using causal analysis. Am J Respir Crit Care Med. 2011;184(10):1133-1139. ],[ANCHOR=View Abstract],[LINK=/content/covidien/websites/medtronic/com/en/covidien/support/clinical-evidence.html?id=476875]) (30 Day)	4.40%
Bekaert 2011⁶ (60 Day)	5.90%

Hospital Length of Stay (LOS) May Increase in Patients with VAP Versus Controls

Back

Hospital Length of Stay (LOS) May Increase in Patients with VAP Versus Controls

	VAP Hospital LOS	Control Hospital LOS	Difference
Warren 2003² (p< 0.001)	38	13	25
Rello 2002³ (p< 0.001)	25.5	14	11.5
Kollef 2005⁵ (p< 0.0001)	23	7.5	15.5

ICU Length of Stay (LOS) May Increase in Patients with VAP Versus Controls

Back

ICU Length of Stay (LOS) May Increase in Patients with VAP Versus Controls

	VAP ICU LOS	Control ICU LOS	Difference
Bercault 2001¹ (p< 0.0001)	31	26	5
Warren 2003² (p< 0.001)	26	4	22
Rello 2002³ (p< 0.001)	11.7	5.6	6.1

Hospital Costs May Increase in Patients with VAP Versus Controls

Back

Hospital Costs May Increase in Patients with VAP Versus Controls

	VAP Costs	Control Costs	Difference
Warren 2003² (p< 0.001)	$70,568	$21,620	$48,948
Rello 2002³ (p< 0.001)	$104,983	$63,689	$41,294
Kollef 2005⁵ (p< 0.0001)	$150,841	$25,218	$125,623
Hugonnet 2004([FOOTNOTE=Hugonnet S, Eggimann P, Borst F, Maricot P, Chevrolet JC, Pittet D. Impact of ventilator-associated pneumonia on resource utilization and patient outcome. Infect Control Hosp Epidemiol. 2004;25(12):1090-1096.],[ANCHOR=View Abstract],[LINK=/content/covidien/websites/medtronic/com/en/covidien/support/clinical-evidence.html?id=277906]) (p< 0.001)	$24,727	$17,438	$7,289

Bibliography of VAP Evidence

View a list of studies used on this site.